Sunisam 25mg Capsules: Clinical Applications, Global Sourcing, and Oncology Procurement Guide
In the evolving field of targeted cancer therapy, Sunisam 25mg (Sunitinib) is an essential multi-kinase inhibitor designed to treat specific solid tumors. For healthcare providers, licensed distributors, and oncology institutions in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, identifying a reliable international source for Sunitinib is a priority for maintaining high standards of patient care.
As an established pharmaceutical exporter from India, Ernest Oncology facilitates the global distribution of Sunisam 25mg, bridging the gap between advanced manufacturing and clinical demand.
Comprehensive Product Profile: Sunisam 25mg
Sunisam 25mg contains the active pharmaceutical ingredient Sunitinib Malate. It is an oral therapy belonging to the class of medications known as tyrosine kinase inhibitors (TKIs). Unlike traditional chemotherapy, Sunisam is a targeted therapy that identifies and attacks specific cancer cells with less damage to normal cells.
Key Clinical Indications
Metastatic Renal Cell Carcinoma (mRCC): Sunisam is a frontline treatment for advanced kidney cancer, helping to stop the progression of the disease.
Gastrointestinal Stromal Tumor (GIST): It is indicated for patients who have not responded to imatinib or who cannot tolerate its side effects.
Pancreatic Neuroendocrine Tumors (pNET): Specifically used for progressive, well-differentiated tumors in the pancreas that are surgically unresectable.
Pharmacology and Mechanism of Action
Sunisam 25mg works by inhibiting multiple receptor tyrosine kinases (RTKs) involved in tumor growth, pathologic angiogenesis (the formation of new blood vessels), and metastatic progression.
VEGFR & PDGFR Inhibition: By blocking these receptors, Sunisam effectively "starves" the tumor of the blood and nutrients it needs to grow.
Direct Anti-Tumor Activity: It interferes with the cellular signaling pathways that tell cancer cells to multiply and spread.
Why Source Sunisam 25mg from Ernest Oncology?
Choosing Ernest Oncology as your bulk supplier provides several clinical and commercial benefits:
Stringent Quality Control: We supply Sunisam manufactured in world-class facilities that meet international GMP standards.
Export Expertise: From London to Abu Dhabi, we manage the complex paperwork required for seamless customs clearance.
Cost-Effective Solutions: Our position as a leading Indian exporter allows us to offer competitive bulk pricing for institutional buyers.
Reliable Logistics: Specialized packaging ensures the therapeutic integrity of Sunisam 25 mg is maintained throughout the international transit process.
Clinical Administration and Safety
Dosage: Sunisam is typically taken once daily. For RCC/GIST, the common cycle is 50 mg (or two 25 mg capsules) daily for 4 weeks, followed by a 2-week break. (Follow the physician's exact prescription).
Monitoring: Regular monitoring of blood pressure, thyroid function, and cardiac enzymes is recommended during treatment.
Storage: Store at room temperature (below 30°C) in a dry place. Keep the container tightly closed to protect from moisture.
📞 Contact Ernest Oncology—Pharmaceutical Exporter from India
[GROUP OF ERNEST PHARMACEUTICAL PVT. LTD]
For bulk inquiries, official quotes, and shipping timelines for Sunisam 25 mg Capsules, reach out to our global export team.
🌐 Websites:
📧 Email:
exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp:
+91 93599 02383 🔗 Direct Chat:
https://wa.me/919359902383
